It would be a precautionary measure, said the Ministry of Health, pending the results of analyses from the European Medicines Agency (EMA) relating to a number of blood problems that have occurred in people vaccinated with the vaccine.
The decision would concern both initial and follow-up vaccinations. An evaluation by the EMA is expected later this week. The agency issued a press release on Monday remaining of the opinion that the benefits of AstraZeneca’s vaccine in preventing Covid-19 outweigh the risks of potential side effects.
Meanwhile, 90% fewer doses of the vaccine are expected to be delivered next week.
